FINAL REPORT HIV Serology External Quality Assessment Scheme
|
|
- Jeffery Brooks
- 7 years ago
- Views:
Transcription
1 FINAL REPORT HIV Serology External Quality Assessment Scheme Programme codes: HIVC4310, HIVC435 Panel ID: 2008/Mar/11 HIV Serology EQAS Panel ID 2008/Mar/11 Page 1 of 12
2 The NRL is a: NATA-accredited proficiency testing provider, complying with ILAC-G13:2000 WHO Collaborating Centre on HIV/AIDS Report prepared by Kathy Smeh and distributed in the week beginning 20008/Mar/31 National Serology Reference Laboratory, Australia (NRL) 4 th Floor, Healy Building, 41 Victoria Parade, Fitzroy, Victoria 3065 Australia HIV Serology EQAS Panel ID 2008/Mar/11 Page 2 of 12
3 1 INTRODUCTION The National Serology Reference Laboratory, Australia (NRL) distributes three Human Immunodeficiency Virus (HIV) Serology External Quality Assessment Scheme (EQAS) panels each year to participants that conduct HIV serology testing. The NRL manages its EQAS using the DigitalPT informatics system (DigitalPT) developed and operated by HealthMetrx Canada Inc. (HMX). AcroMetrix Corporation and its subsidiaries (AcroMetrix) provide logistical support for participants enrolled through AcroMetrix. All participants in the NRL s EQAS are provided with a unique and confidential identifier. This identifier is known only by participants, NRL, HMX and AcroMetrix. This report presents and discusses the results reported for HIV Serology EQAS Panel ID 2008/Mar/11. The aims of this panel were to: investigate instances of sample carryover, particularly on automated analysers; examine testing strategies used by participants; examine the integrity of result reporting. 1.1 Copyright The information and data included in this report are the intellectual property of the NRL, a division of St Vincent s Institute. They may not be reproduced, in whole or in part, for any purpose without the written permission of the NRL; nor may they be used in any type of advertising or sales promotion. 2 METHODS 2.1 Panel composition, preparation and distribution The HIV Serology EQAS panel for programme code HIVC4310 consisted of ten plasma samples. The HIV Serology EQAS panel for programme code HIVC435 consisted of five samples which were the same as the first five samples included in the panel for programme code HIVC4310. The HIV reactivity of each sample is detailed in Tables A1 and A2. The samples were obtained from blood donors from Africa, Australia and Southeast Asia. Each pooled sample was prepared by mixing equal volumes of at least two samples that were from the same country of origin and that had similar antibody and antigen profiles. The samples were tested by the NRL in a range of assays to confirm their reactivity (Table A2). The samples were aliquotted and their homogeneity was confirmed by testing conducted at the NRL. Representative samples were tested by the NRL following shipment to participants to confirm their stability. HIV Serology EQAS Panel ID 2008/Mar/11 was distributed to 206 participants in 38 countries. HIV Serology EQAS Panel ID 2008/Mar/11 Page 3 of 12
4 2.2 Evaluation of results Qualitative evaluation Results reported by participants for assay interpretations and status were compared with the relevant reference results (Tables A1 and A2). In instances where an assay interpretation was not provided for a sample tested in a rapid or agglutination assay, the reactivity for the sample that was reported by the participant was taken to also be the assay interpretation. An aberrant assay interpretation is one that did not agree with the relevant reference result. An aberrant status is one that did not agree with the relevant reference result or consensus status (if applicable) Statistical analyses Tukey s Outlier Filter was used to identify outlying results. An outlying test result is a numerical test result that is found to be statistically different from other test results reported by participants that tested the same sample in the same assay. Occasionally the EQAS coordinator may manually flag a result as outlying, which will cause it to be removed from the statistical analysis. This will only occur when inclusion of the result will erroneously bias the statistical analysis e.g. when the result is from the testing of an incorrect sample. 3 RESULTS Results from 187 participants were received for HIV Serology EQAS Panel ID 2008/Mar/11. Results were not received by the closing date for the acceptance of results from Participants NRL0014, NRL0016, NRL0100, NRL0146, NRL0183, NRL0276, NRL0346, NRL0347, NRL0348, NRL0351, NRL0352, NRL0353, NRL0354, NRL0355, NRL0356, NRL0439, NRL0485, NRL0501 and NRL0525. Participant NRL0276 contacted the NRL after panels had been distributed and indicated that it was not able to test the panel because it had temporarily ceased testing for HIV. Participants NRL0076, NRL0091, NRL0092, NRL0095, NRL0101, NRL0117, NRL0128 and NRL0321 used kits that had expired. The NRL does not recommend the use of kits once the expiry date has passed and urges participants to check expiry dates prior to testing. All participants that reported outlying test results, aberrant assay interpretations or results that warranted comment are listed in Table 1. Each participant is advised to check Table 1 and to review Section 4 (DISCUSSION), which comments on other results that may need review. HIV Serology EQAS Panel ID 2008/Mar/11 Page 4 of 12
5 Table 1. Participants that reported outlying test results, aberrant assay interpretations or status, or results that warranted comment Laboratory ID* Sample ID Reference Result Assay Outlying Test Results** NRL0010 E Negative Abbott PRISM HIV O Plus ChLIA NRL0012 F Negative Abbott ARCHITECT HIV Ag/Ab Combo CMIA Type of Result Identified Aberrant Assay Interpretations*** NRL0018 B, C, D, H, I Positive NRL0026 B, C, D, H, I Positive Aberrant Status**** NRL0029 B, C, D, H, I Positive NRL0030 J Negative Abbott ARCHITECT HIV Ag/Ab Combo CMIA NRL0049 B, C, D, H, I Positive NRL0060 J Negative Abbott IMx HIV-1/HIV-2 III Plus MEIA Negative NRL0062 B, C, D, H, I Positive NRL0066 B, C, D, H, I Positive NRL0075 A, E, F, G, J Negative MP Diagnostics HIV BLOT 2.2 WB NRL0084 A Negative NRL0090 A, E, F, G, J Negative J. Mitra HIV WB NRL0099 G Negative Bio-Rad Genscreen Plus HIV Ag-Ab EIA NRL0109 p24 Ag B, C, D, H, I biomerieux VIDAS HIV DUO Ultra ELFA Negative J Negative NRL0113 A, E, F, G, J Negative Bio-Rad NEW LAV BLOT 1 WB NRL0115 A Negative Abbott ARCHITECT HIV Ag/Ab Combo CMIA NRL0119 F Negative Abbott ARCHITECT HIV Ag/Ab Combo CMIA B, C, D, H, I Positive NRL0126 E, J Negative Abbott ARCHITECT HIV Ag/Ab Combo CMIA NRL0138 A Negative Abbott PRISM HIV O Plus ChLIA Miscellaneous Comments HIV Serology EQAS Panel ID 2008/Mar/11 Page 5 of 12
6 Table 1. Participants that reported outlying test results, aberrant assay interpretations or status, or results that warranted comment (continued) Laboratory ID* Sample ID Reference Result Assay Outlying Test Results** Type of Result Identified Aberrant Assay Interpretations*** NRL0144 B, C, D, H, I Positive NRL0150 B, C, D, H, I Positive NRL0161 G Negative Abbott AxSYM HIV 1/2 go MEIA NRL0162 J Negative Bayer ADVIA Centaur HIV1/O/2 Enhanced (EHIV) Assay NRL0174 G Negative Abbott AxSYM HIV Ag/Ab Combo MEIA NRL0180 B, C, D, H, I Positive Negative Abbott AxSYM HIV 1/2 go MEIA NRL0235 J Negative NRL0248 J Negative Abbott Murex HIV-1.2.O EIA NRL0249 B, D Reactive biomerieux Vironostika HIV Uni-Form II Plus O ELISA NRL0250 B, C, D, H, I Positive NRL0282 G Negative Ortho Vitros Anti-HIV 1+2 Assay Abbott Determine HIV-1/2 Immunoassay Negative G Fujirebio SFD HIV-1/2 Negative NRL0292 Abbott Determine HIV-1/2 Immunoassay Reactive I Fujirebio SFD HIV-1/2 Positive NRL0305 E, J Negative Abbott ARCHITECT HIV Ag/Ab Combo CMIA Aberrant Status**** NRL0373 A, E, F, G, J Negative Bio-Rad NEW LAV BLOT 1 WB NRL0421 B, C, D, H, I Positive NRL0427 A, E, F, G, J Negative MP Diagnostics HIV BLOT 2.2 WB NRL0441 B, C, D, H, I Reactive Bio-Rad Genscreen HIV-1/2 Version 2 EIA Miscellaneous Comments A, E, F, G, J Negative Innogenetics INNO-LIA HIV I/II Score HIV Serology EQAS Panel ID 2008/Mar/11 Page 6 of 12
7 Table 1. Participants that reported outlying test results, aberrant assay interpretations or status, or results that warranted comment (continued) Laboratory ID* Sample ID Reference Result Assay Outlying Test Results** Type of Result Identified Aberrant Assay Interpretations*** Aberrant Status**** NRL0460 A, E Negative Chiron RIBA HIV-1/HIV-2 SIA NRL0481 A Negative biomerieux Vironostika HIV Uni-Form II Plus O ELISA Miscellaneous Comments B, D Reactive biomerieux Vironostika HIV Uni-Form II Plus O ELISA C, H, I Reactive biomerieux Vironostika HIV Uni-Form II Plus O ELISA J Negative biomerieux Vironostika HIV Uni-Form II Plus O ELISA B, C, D, H, I Reactive Li Zhu Diagnostic Kit for Antibody to HIV (Sandwich ELISA) NRL0487 B, C, D, H, I Positive NRL0500 B, C, D, H, I Positive Note: * Identification. ** An outlying test result is a numerical test result that is found to be statistically different from the other test results reported by participants that tested the same sample in the same assay. *** An aberrant assay interpretation is one that did not agree with the relevant reference result. **** An aberrant status is one that did not agree with the relevant reference result or consensus status (if applicable). HIV Serology EQAS Panel ID 2008/Mar/11 Page 7 of 12
8 4 DISCUSSION Six participants each reported at least one assay interpretation that was considered to be aberrant. Nineteen participants each reported at least one status that was considered to be aberrant. Participants NRL0018, NRL0026, NRL0049, NRL0062, NRL0066, NRL0119, NRL0144, NRL0150, NRL0180, NRL0250, NRL0441, NRL0487 and NRL0500 each assigned an aberrant HIV serology status to the HIV positive samples B, C, D, H and I. The participants assigned an inconclusive/indeterminate status based on testing all samples in a single assay (except for Participant NRL0500 that used two assays). In addition, all participants that assigned a serology status to the HIV positive samples B, C, D, H and I after testing in only one assay should note the following: When performing serological testing, participants use a variety of testing strategies that may involve testing with a combination of screening, supplemental and/or confirmatory assays. A final serology status (final interpretation) of positive, negative or indeterminate should only be assigned to a sample after consideration of all test results (screening, supplemental and confirmatory). Participants that test samples using only one assay should refer any reactive samples for further testing in order to distinguish true from false reactivity. When reporting a final interpretation in DigitalPT, a participant that would not report a status/final interpretation but would refer a sample for further testing should submit their results as: Serology Status Refer for Further Testing Select problem code Do not select any option Do not select any option Would not report a status based on these results Otherwise, participants that would report a status/final interpretation should assign an appropriate status and select No for Refer for Further Testing. Participant NRL0029 tested all of the panel samples once in the Abbott AxSYM HIV Ag/Ab Combo MEIA. The participant obtained reactive results for the HIV positive samples B, C, D, H and I and indicated that these samples would be referred for further testing. The participant also indicated that it would assign a positive status to each of these samples but that it also Would not report a status based on the results obtained. Participant NRL0060 tested all of the panel samples once in the Abbott IMx HIV-1/HIV-2 III Plus MEIA. The participant obtained a reactive test result that was over the cut-off for the assay (S:Co 6.34) for the HIV negative sample J. The test result obtained for sample J may be due to sample carry over because the two samples preceding sample J in the panel were HIV positive samples. The result does not appear to be due to testing a positive sample twice because the S/Co values obtained by the participant for the HIV positive panel samples were substantially higher than the result obtained for sample J. No other participant that tested the sample in the same assay reported a reactive assay interpretation for the sample. Participant NRL0060 assigned a status to all of the panel samples even though the participant indicated that it would refer all of the samples for further testing. Participant NRL0084 assigned a positive HIV status to the HIV negative sample A. Following the release of the preliminary report, Participant NRL0084 contacted the NRL and indicated that difficulty had been experienced with data entry into DigitalPT, especially for sample A. Participant NRL0084 indicated that it was necessary to enter the results for sample A twice and that an error had occurred. This participant was inexperienced in the use of DigitlPT. Participants that experience difficulty with DigitalPT should refer to the DigitalPT User Guide and/or contact the NRL. The DigitalPT user Guide is available from the DOCUMENTS section of the DigitalPT website. HIV Serology EQAS Panel ID 2008/Mar/11 Page 8 of 12
9 Participant NRL0099 tested all of the panel samples in the Abbott Determine HIV-1/2 Immunoassay and reported results that agreed with the reference results. The participant then proceeded to test all of the samples once in each of two test runs in the Bio-Rad Genscreen Plus HIV Ag-Ab EIA. The participant reported reactive results that were just above the cut-off for the assay (S:Co 1.99; 4.77) for the HIV negative sample G. The participant interpreted sample G to be reactive in the Bio-Rad Genscreen Plus HIV Ag-Ab EIA. All of the other participants that had tested sample G in the same assay had reported results that agreed with the reference results. The participant then proceeded to test the sample in an immunoblot and obtained a negative immunoblot result for the sample. The participant assigned a negative HIV status to the sample. Participant NRL0109 tested all of the panel samples in the biomerieux VIDAS HIV DUO Ultra ELFA. The participant reported reactive p24 antigen test results and assay interpretations for samples B, C, D, H and I. The assay interpretations for these samples were considered to be aberrant. All of the panel samples were negative for p24 antigen. Two other participants had tested samples B, C, D, H and I for p24 antigen in the same assay and reported negative results. Three participants had tested all of the panel samples in the same assay and reported reactive anti-hiv-1/2 test results and assay interpretations for samples B, C, D, H and I. It appears that Participant NRL0109 had tested the panel samples in the biomerieux VIDAS HIV DUO Ultra ELFA only for anti-hiv-1/2 and had reported these results as p24 antigen results. Participant NRL0109 also assigned a positive HIV status to the HIV negative sample J. This aberrant status may be due to a clerical error (based on the results that were reported) because the participant had reported negative anti-hiv-1/2 (Innovacon HIV 1/2/O Tri-line HIV Rapid Test Device) and p24 antigen (biomerieux VIDAS HIV DUO Ultra ELFA) assay interpretations for the sample, which agreed with the reference results for the sample. Participant NRL0235 tested all of the panel samples once in the Abbott AxSYM HIV 1/2 go MEIA. The participant had reported a reactive test result that was interpreted as reactive for the HIV negative sample J. The test result obtained for sample J may be due to sample carry over because the two samples preceding sample J in the panel were HIV positive samples. The result does not appear to be due to testing an HIV sample twice because the S:Co values obtained by the participant for the HIV positive panel samples were higher than the result obtained for sample J. No other participant that tested sample J in the same assay reported a reactive assay interpretation for the sample. Participant NRL0235 assigned a positive HIV status to sample J. The participant however also indicated that it would refer the sample for further testing. The assay manufacturer for the assay concerned recommends, in the package insert that is available in Australia, that samples that are reactive on initial testing be retested in duplicate. Had the participant retested sample J in duplicate, the participant may have obtained negative test results and been able to interpret the sample as negative. Participant NRL0292 had tested all of the samples once in the Bio-Rad Genscreen Plus HIV Ag-Ab EIA and had reported test results and assay interpretations for all of the samples that agreed with the reference results. The participant then tested all of the samples once in each of two supplemental assays: Fujirebio SFD HIV-1/2 and Abbott Determine HIV-1/2 Immunoassay. The participant reported reactive results for the HIV negative sample G and negative results for the HIV positive sample I in each of the supplemental assays. All of the other participants that tested samples G and I in the same assays reported results that agreed with the reference results. The participant assigned a positive status to sample G and a negative status to sample I. The aberrant results may be due to a sample mix-up that occurred after the testing in the Bio-Rad Genscreen Plus HIV Ag-Ab EIA had taken place. The aberrant results may also be due to human error and /or the individual interpretation of the results obtained for the supplemental assays. Both of the supplemental assays used are read subjectively. Subjectively read assays are prone to human error and/or individual interpretation. The NRL recommends that two operators score subjectively read assays independently of each other, and that a third opinion is sought if they disagree. It is also recommended that staff are periodically assessed for competence following initial training. HIV Serology EQAS Panel ID 2008/Mar/11 Page 9 of 12
10 Participant NRL0481 tested all of the panels samples twice, once in each of two assays: biomerieux Vironostika HIV Uni-Form II Plus O ELISA and Li Zhu Diagnostic Kit for Antibody to HIV (Sandwich ELISA). The participant reported a reactive assay interpretation for the HIV negative sample A in the biomerieux Vironostika HIV Uni-Form II Plus O ELISA, which appears to be due to a clerical error. The participant reported obtaining a S:Co value of 0.05 for sample A which was interpreted as reactive. However, the participant had also reported the same S:Co value for two other samples that had been tested in the same assay which were interpreted as negative. The participant reported a negative assay interpretation for sample A in the Li Zhu Diagnostic Kit for Antibody to HIV (Sandwich ELISA). The participant did not indicate whether or not any of the panel samples would be referred for further testing or whether a status would be assigned to any of the panel samples. Participant NRL0481 reported results for samples found to be reactive as S:Co 3.00 rather than as > 3.00 in all of the assays used. Consequently, these test results were included in statistical analyses (where a peer group was able to be formed). The reactive test results for samples B, D and J in the biomerieux Vironostika HIV Uni-Form II Plus O ELISA were identified to be outlying. Participants NRL0075, NRL0090, NRL0113, NRL0373, NRL0427, NRL0441 and NRL0460 tested all of the panel samples in an immunoblot irrespective of the screening results obtained. A screening assay is a first line assay used to test all samples. Supplemental and confirmatory assays are used to test samples repeatedly reactive in the screening assay to differentiate true from false reactivity. Samples that are not reactive in a screening assay should not be tested in immunoblots because the samples may display non-specific reactivity and then be reported unnecessarily as indeterminate. On this occasion, the participants did not report any aberrant immunoblot interpretations. Acknowledgements The NRL thanks our colleagues who supply samples for the EQAS. We thank all our participants for their cooperation. Comments or queries about this report, or about any problems you might experience with HIV serology testing, will be welcomed by Kathy Smeh on or via on kathy@nrl.gov.au. HIV Serology EQAS Panel ID 2008/Mar/11 Page 10 of 12
11 5 APPENDIX Table A1. Composition of HIV Serology EQAS Panel ID 2008/Mar/11 Sample Identification by Programme Sample Origin Sample Type HIV Status HIVC4310 HIVC435 A A Australian blood donors Pooled plasma Negative B B African blood donors Pooled plasma Positive C C Southeast Asian blood donors Pooled plasma Positive D D Southeast Asian blood donors Pooled plasma Positive E E Australian blood donors Pooled plasma Negative F Not applicable Australian blood donors Pooled plasma Negative G Australian blood donors Pooled plasma Negative H African blood donors Pooled plasma Positive I Southeast Asian blood donors Pooled plasma Positive J Australian blood donors Pooled plasma Negative HIV Serology EQAS Panel ID 2008/Mar/11 Page 11 of 12
12 Table A2. Characterisation of the samples that comprised HIV Serology EQAS Panel ID 2008/Mar/11 Sample Identification by Programme HIVC4310 HIVC435 Test Result (S/Co*) Abbott Murex HIV-1.2.O Assay Interpretation Bio-Rad Genetic Systems HIV-1 Ag EIA Test Result (S/Co) Assay Interpretation Bio-Rad Genetic Systems HIV-1 Ag Confirmatory Test Result Assay Interpretation NRL In-house HIV-1 WB p18 p24 p31 p34 gp41 p53 p68 Assay Interpretation A A 0.38 Negative 0.09 Negative Not tested Not applicable Not tested Not applicable Negative B B Reactive 0.12 Negative Not tested Not applicable Positive Positive C C Reactive 0.11 Negative Not tested Not applicable Positive Positive D D Reactive 0.12 Negative Not tested Not applicable Positive Positive E E 0.29 Negative 0.12 Negative Not tested Not applicable Not tested Not applicable Negative F Not 0.34 Negative 0.12 Negative Not tested Not applicable Not tested Not applicable Negative G applicable 0.29 Negative 0.11 Negative Not tested Not applicable Not tested Not applicable Negative H Reactive 0.12 Negative Not tested Not applicable Positive Positive I Reactive 0.10 Negative Not tested Not applicable Positive Positive J Note: * Sample to cut-off ratio, where 1 is reactive Negative 0.11 Negative Not tested Not applicable Not tested Not applicable Negative HIV Status HIV Serology EQAS Panel ID 2008/Mar/11 Page 12 of 12
INTERPRETATION INFORMATION SHEET
Creative Testing Solutions 2424 West Erie Dr. 2205 Highway 121 10100 Martin Luther King Jr. St. No. Tempe, AZ 85282 Bedford, TX 76021 St. Petersburg, FL 33716 INTERPRETATION INFORMATION SHEET Human Immunodeficiency
More informationHepatitis and Retrovirus. LIAISON XL Accurate detection of HIV infection. HIV Ab/Ag FOR OUTSIDE THE US AND CANADA ONLY
Hepatitis and Retrovirus LIAISON XL Accurate detection of HIV infection HIV Ab/Ag FOR OUTSIDE THE US AND CANADA ONLY LIAISON XL HIV Ab/Ag is Your solution LIAISON XL murex HIV Ab/Ag main features The LIAISON
More informationWHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: Genscreen ULTRA HIV Ag-Ab Number: PQDx 0096-031-00. Abstract
WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: Genscreen ULTRA HIV Ag-Ab Number: PQDx 0096-031-00 Abstract Genscreen ULTRA HIV Ag-Ab with product codes 72386 and 72388, manufactured
More informationSuggested Reporting Language for the HIV Laboratory Diagnostic Testing Algorithm
Suggested Reporting Language for the HIV Laboratory Diagnostic Testing Algorithm November 2013 Introduction In March 2010, the Centers for Disease Control and Prevention (CDC) and the Association of Public
More information(EMEA/CHMP/BWP/298390/2005)
9 February 2006 Reference: EMEA 06004 PPTA s comments on the proposed Guidelines on Validation of immunoassays for the detection of Hepatitis B Virus surface antigen (HBsAg) (EMEA/CHMP/BWP/298390/2005)
More informationLIAISON XL HBsAg Quant
Hepatitis and Retrovirus LIAISON XL HBsAg Quant Reliable detection of HBsAg mutants and genotypes for accurate differential diagnosis of the stage of infection FOR OUTSIDE THE US AND CANADA ONLY LIAISON
More informationGLOBAL FUND QUALITY ASSURANCE POLICY FOR DIAGNOSTICS PRODUCTS. (Issued on 14 December 2010, amended on 5 February 2014)
GLOBAL FUND QUALITY ASSURANCE POLICY FOR DIAGNOSTICS PRODUCTS (Issued on 14 December 2010, amended on 5 February 2014) BASIC PRINCIPLES 1. Grant funds provided by the Global Fund may only be used to procure
More informationBEIPH Final Report. QCMD 2010 Hepatitis B Virus DNA (HBVDNA10A) EQA Programme. William G MacKay on behalf of QCMD and its Scientific Council July 2010
QUALITY CONTROL for MOLECULAR DIAGNOSTICS The Altum Building, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA Scotland Tel: +44 (0) 141 945 6474 Fax: +44 (0) 141 945 5795 www.qcmd.org info@qcmd.org
More informationTRI-LEVEL CARDIAC CONTROL (CRD CONTROL 1, 2, 3)
TRI-LEVEL CARDIAC CONTROL (CRD CONTROL 1, 2, 3) CAT NO. CQ3259 LOT NOS. 3190CK, 3191CK, 3192CK SIZE: 3 x 2ml EXPIRY: 2015-02 INTENDED USE This product is intended for in vitro diagnostic use in the quality
More informationin hiv diagnostics the role of phls
Issues in Brief: HIV Diagnostics UPDATE Association of Public Health Laboratories August 2011 Conference calls Focus on New trends in hiv diagnostics the role of phls In February 2011, the Association
More informationBlood Screening Assays. CTS lab locations where assays are performed are indicated by alpha codes D, P, and T.
Blood Screening Assays CTS lab locations where assays are performed are indicated by alpha codes D, P, and T. D= performed in Dallas lab FEI: 3002580251 P= performed in Phoenix lab FEI: 3000204058 T= performed
More information510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY
A. 510(k) Number: K092353 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY B. Purpose for Submission: This is a new 510k application for a new indication for the MONOLISA Anti-HAV IgM EIA
More informationHIV SIMPLE/RAPID ASSAYS: OPERATIONAL CHARACTERISTICS
WHO/BCT/2.7 HIV SIMPLE/RAPID ASSAYS: OPERATIONAL CHARACTERISTICS (PHASE I) REPORT 2 WHOLE BLOOD SPECIMENS Blood Safety and Clinical Technology January 22 World Health Organization GENEVA Copyright World
More informationDiagnosis of HIV-1 Infection. Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University
Diagnosis of HIV-1 Infection Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University Tests Used to Diagnose HIV-1 Infection HIV antibody (today s topic) HIV p24 antigen HIV DNA HIV
More informationLIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection
Hepatitis and Retrovirus LIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection FOR OUTSIDE THE US AND CANADA ONLY LIAISON XL HCV Ab is Your solution LIAISON XL murex HCV Ab main features
More informationQuality Assurance Guidelines for Testing Using Rapid HIV Antibody Tests Waived Under the Clinical Laboratory Improvement Amendments of 1988
Quality Assurance Guidelines for Testing Using Rapid HIV Antibody Tests Waived Under the Clinical Laboratory Improvement Amendments of 1988 U.S. Department of Health and Human Services Centers for Disease
More informationObjectives. Immunologic Methods. Objectives. Immunology vs. Serology. Cross Reactivity. Sensitivity and Specificity. Definitions
Immunologic Methods Part One Definitions Part Two Antigen-Antibody Reactions CLS 420 Clinical Immunology and Molecular Diagnostics Kathy Trudell MLS (ASCP) CM SBB CM ktrudell@nebraskamed.com Discuss the
More informationDevelopment and Validation of In Vitro Diagnostic Tests. YC Lee, Ph.D. CEO
Development and Validation of In Vitro Diagnostic Tests YC Lee, Ph.D. CEO 1 Validation of In Vitro Diagnostic Tests Validated d Diagnostic Test should: Provides test results that identify if positive i
More informationHIV ASSAYS: OPERATIONAL CHARACTERISTICS
HIV ASSAYS: OPERATIONAL CHARACTERISTICS (PHASE I) REPORT URINE SPECIMENS ORAL FLUID (SALIVA) SPECIMENS World Health Organization HIV ASSAYS: OPERATIONAL CHARACTERISTICS (PHASE I) REPORT URINE SPECIMENS
More informationTesting Oral Presence of
Issues in Brief: Oral Fluid Testing for HIV Antibodies February 2013 Testing Oral Fluid for the Presence of HIV Antibodies 2013 Status Report HIV testing is primarily done using blood-based specimens (fingerstick
More informationLAB 14 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
STUDENT GUIDE LAB 14 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) GOAL The goal of this laboratory lesson is to explain the concepts and technique of enzyme linked immunosorbent assay (ELISA). OBJECTIVES
More informationPreamble: Explaining the Technical Aspects of HIV Testing
Preamble: Explaining the Technical Aspects of HIV Testing A. What is the difference between an antibody, antigen, viral load and CD-4 count? The presence of an HIV infection in a person can be determined
More informationViral Hepatitis. 2009 APHL survey report
Issues in Brief: viral hepatitis testing Association of Public Health Laboratories May Viral Hepatitis Testing 9 APHL survey report In order to characterize the role that the nation s public health laboratories
More informationPremarital Screening Standard. Premarital Screening and Counseling Program. Version 1.1
Premarital Screening Standard Premarital Screening and Counseling Program Version 1.1 July 2013 Table of Contents Page Table of Contents 1 Table of Appendixes 2 Abbreviation list 3 Introduction 4 PS.1
More informationThe Problem of the Use of different Units for the same Analyte
The Problem of the Use of different Units for the same Analyte EQALM Symposium 2009 Ulla Tiikkainen ulla.tiikkainen @labquality.fi Comparability of results Measurement traceability to the reference material
More informationAcute infections, cost per infection and turnaround time in three U.S. hospital laboratories
1 Acute infections, cost per infection and turnaround time in three U.S. hospital laboratories using fourth-generation antigen-antibody HIV immunoassays Laura G. Wesolowski 1,*, Muazzam Nasrullah 1, Robert
More informationFEDERAL PUBLIC SERVICE, HEALTH, FOOD CHAIN SECURITY AND ENVIRONMENT CLINICAL BIOLOGY COMMISSION CLINICAL BIOLOGY SECTION
IPH J. Wytsmanstreet 14 B-1050 Brussels FEDERAL PUBLIC SERVICE, HEALTH, FOOD CHAIN SECURITY AND ENVIRONMENT CLINICAL BIOLOGY COMMISSION CLINICAL BIOLOGY SECTION External Quality Assessment for Molecular
More informationHIV DIAGNOSIS: A GUIDE FOR SELECTING RAPID DIAGNOSTIC TEST (RDT) KITS
HIV DIAGNOSIS: A GUIDE FOR SELECTING RAPID DIAGNOSTIC TEST (RDT) KITS 1) Overview There are nearly 33 million people infected with the human immunodeficiency virus (HIV) world wide. Sub-Saharan Africa
More informationDirect Testing Systems and Serology
Direct Testing Systems and Serology Rapid Manual Tests 6-2 Serology Diagnostics 6-6 BD Diagnostics Diagnostic Systems Catalog 2005/2006 6-1 Rapid Manual Tests Meningitis Test Systems 252360 Directigen
More informationIMMUNOASSAY PREMIUM PLUS LEVEL 3 (IA PREMIUM PLUS 3)
0843 IMMUNOASSAY PREMIUM PLUS LEVEL 3 (IA PREMIUM PLUS 3) Cat. No.: IA3111 / IA3112 Lot No.: 1130EC Size.: 12 x 5ml / 12 x 5ml Expiry.: 2014-10 INTENDED USE This product is intended for in vitro diagnostic
More informationIMMUNOASSAY CONTROL - LEVEL 1 (IA CONTROL 1)
0843 IMMUNOASSAY CONTROL - LEVEL 1 (IA CONTROL 1) Cat. No. IA2638 / IA2633 Lot No. 978EC Size: 10 x 5 ml / 12 x 5 ml Expiry: 2013-10 INTENDED USE This product is intended for in vitro diagnostic use in
More informationfor Leucocyte Immunophenotyping Leukaemia Diagnosis Interpretation All Participants Date Issued: 08-September-2014 Closing Date: 26-September-2014
for Leucocyte Immunophenotyping Leukaemia Interpretation All Participants Participant: 4xxxx Trial No: 141502 Date Issued: 08-September-2014 Closing Date: 26-September-2014 Trial Comments This was an electronic
More informationD-Facts. Vitamin D Competitive Evaluation
D-Facts Vitamin D Competitive Evaluation Abstract 101 patient samples collected across sites in Germany were used to compare the performance of the Siemens ADVIA Centaur Vitamin D Total (VitD), Abbott
More informationHow Does a Doctor Test for AIDS?
Edvo-Kit #S-70 How Does a Doctor Test for AIDS? S-70 Experiment Objective: The Human Immunodefi ciency Virus (HIV) is an infectious agent that causes Acquired Immunodefi ciency Syndrome (AIDS) in humans.
More informationReducing the Diagnostic Window for Acute HIV
Reducing the Diagnostic Window for Acute HIV ARCHITECT HIV Ag/Ab Combo See intended use and important safety information on the next page. The Clinical and Economic Value of Early Detection Using 4 th
More informationBlood, Plasma, and Cellular Blood Components INTRODUCTION
Blood, Plasma, and Cellular Blood Components INTRODUCTION This chapter of the Guideline provides recommendations to Sponsors of Requests for Revision for new monographs for blood, plasma, and cellular
More informationTEST METHOD VERIFICATION AND VALIDATION
1 TEST METHOD VERIFICATION AND VALIDATION SWACM 2014 MICHAEL LOEFFELHOLZ, PH.D., ABMM DEPT. PATHOLOGY UNIV TEXAS MEDICAL BRANCH GALVESTON, TX 2 OBJECTIVES Define validation and verification Describe components
More informationQuantiFERON TB Gold In Tube Method (QGIT Test) Manufacturer: Cellestis Inc. (USA) a QIAGEN Company
QuantiFERON TB Gold In Tube Method (QGIT Test) Manufacturer: Cellestis Inc. (USA) a QIAGEN Company P1078 TB APPRISE TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed
More informationTypes of HIV test. Antigen - Any substance (such as an immunogen or a hapten) foreign to the body that stimulates an immune system response.
Types of HIV test There are two basic categories of HIV test 4 th generation and 3 rd generation. Each individual test differs as to what it tests (whether antibodies and/or p24 antigens), how it tests
More informationComparative evaluation of 36 commercial assays for detecting antibodies to HIV*
Comparative evaluation of 36 commercial assays for detecting antibodies to HIV* 1. Van kerckhoven,' G. Vercauteren,l P. Piot,2 & G. van der Groen3 Summarized are the results of an assessment of the major
More informationQUALITY MANAGEMENT IN VETERINARY TESTING LABORATORIES
NB: Version adopted by the World Assembly of Delegates of the OIE in May 2012 CHAPTER 1.1.4. QUALITY MANAGEMENT IN VETERINARY TESTING LABORATORIES SUMMARY Valid laboratory results are essential for diagnosis,
More informationDiagnosis and Treatment Regimes for Syphilis By Dr John Bannister
Diagnosis and Treatment Regimes for Syphilis By Dr John Bannister Syphilis: Serological Testing Introduction In an ideal world a practitioner would have assessed a patient s medical history with regards
More informationInitial sensitivity: 100% Final specificity: 98% Initial sensitivity: 99%
List of diagnostics eligible to tender for procurement by WHO in 2014 (including WHO prequalified diagnostics) Since 1988, WHO has performed assessments of commercially available diagnostics for HIV, hepatitis
More informationReporting Service Performance Information
AASB Exposure Draft ED 270 August 2015 Reporting Service Performance Information Comments to the AASB by 12 February 2016 PLEASE NOTE THIS DATE HAS BEEN EXTENDED TO 29 APRIL 2016 How to comment on this
More informationContent Sheet 7-1: Overview of Quality Control for Quantitative Tests
Content Sheet 7-1: Overview of Quality Control for Quantitative Tests Role in quality management system Quality Control (QC) is a component of process control, and is a major element of the quality management
More informationCost Utility Analysis Subgroup. Brian Custer ISBT WP-TTID Cancun, Mexico July 8, 2012
Cost Utility Analysis Subgroup Brian Custer ISBT WP-TTID Cancun, Mexico July 8, 2012 Global risk assessment and cost utility of blood safety interventions development of a webbased application and multi-country
More informationTable. Analytical characteristics of commercial cardiac troponin I and T assays declared by the manufacturer.
Table. Analytical characteristics of commercial cardiac troponin I and T assays declared by the manufacturer. Commercially available assays - Company/ platform(s)/ assay LoB a LoD b 99 th % %CV at 99 th
More informationBLOOD DONOR TESTING & LOOKBACK STUDIES Shan Yuan, MD Last Updated 2/8/2011. 1. ABO Typing: Performed each time with each donation
Testing Performed: BLOOD DONOR TESTING & LOOKBACK STUDIES Shan Yuan, MD Last Updated 2/8/2011 1. ABO Typing: Performed each time with each donation 2. Rh Typing: o Performed along with ABO typing to determine
More informationCustomer Service For additional product information, please contact your local customer service organization.
ABBOTT PRISM HCV Hepatitis C Virus Encoded Antigens (Recombinant c100-3, HCr43, NS5) en ABBOTT PRISM HCV 6A52-48 34-8925/R10 B6A520 Read Highlighted Changes Revised March, 2008 Customer Service For additional
More information100 (20 5) tests 71110 PASSIVE PARTICLE AGGLUTINATION TEST FOR THE DETECTION OF ANTIBODIES TO HIV-1 AND/OR HIV-2 IN HUMAN SERUM OR PLASMA
100 (20 5) tests 71110 PASSIVE PARTICLE AGGLUTINATION TEST FOR THE DETECTION OF ANTIBODIES TO HIV-1 AND/OR HIV-2 IN HUMAN SERUM OR PLASMA IVD For In Vitro Diagnostic Use Manufacturer quality control All
More informationWHO Prequalification of Diagnostics Programme PUBLIC REPORT
WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: ABON HIV 1/2/O Tri-Line Human Immunodeficiency Virus Rapid Test Device Number: PQDx 0141-051-00 Abstract ABON HIV 1/2/O Tri-Line Human
More informationOraQuick HCV Rapid Antibody Test Customer Letter
OraQuick HCV Rapid Antibody Test Customer Letter Dear Customer, Thank you for deciding to use the OraQuick HCV Rapid Antibody Test. The sale, distribution, and use of this product is restricted as described
More informationAssay Migration Studies for In Vitro Diagnostic Devices Guidance for Industry and FDA Staff
Assay Migration Studies for In Vitro Diagnostic Devices Guidance for Industry and FDA Staff Document issued on: April 25, 2013 The draft of this document was issued on January 5, 2009. For questions regarding
More informationCustomer Service For additional product information, please contact your local customer service organization.
Anti-HCV system en Anti-HCV 6C37 48-6176/R6 B6C370 Read Highlighted Changes Revised October, 2009 Customer Service For additional product information, please contact your local customer service organization.
More informationHIV Rapid Test Kits USAID Approval and Technical Guidance June 17, 2013 Revision
HIV Rapid Test Kits USAID Approval and Technical Guidance Revision Part 1 A. Introduction 1. This document contains the requirements for USAID evaluation and approval of HIV rapid test kits and related
More informationSyphilis Fast latex Agglutination Test: A Rapid Confirmatory Test for Syphilis
Syphilis Fast latex Agglutination Test: A Rapid Confirmatory Test for Syphilis Martha B. Fears and Victoria Pope* Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases,
More informationContent Sheet 10-1: Overview of External Quality Assessment (EQA)
Content Sheet 10-1: Overview of External Quality Assessment (EQA) Role in quality management system Assessment is a critical aspect of laboratory quality management, and it can be conducted in several
More informationSMF Awareness Seminar 2014
SMF Awareness Seminar 2014 Clinical Evaluation for In Vitro Diagnostic Medical Devices Dr Jiang Naxin Health Sciences Authority Medical Device Branch 1 In vitro diagnostic product means Definition of IVD
More informationIgM ELISA. For the quantitative determination of IgM in human serum and plasma. For Research Use Only. Not For Use In Diagnostic Procedures.
IgM ELISA For the quantitative determination of IgM in human serum and plasma For Research Use Only. Not For Use In Diagnostic Procedures. Please read carefully due to Critical Changes, e.g., Calibrator
More informationThis is not a valid request for information in accordance with the FOI Act as it does not ask for information held by PHE.
By email Public Accountability Unit Wellington House 133-155 Waterloo Road London SE1 8UG Tel: 020 8327 6920 www.gov.uk/phe Veronica Hughes request-313568-e1ecf364@whatdotheyknow.com Our ref: 01/02/jb/551
More informationCustomer Service For additional product information, please contact your local customer service organization. Key to symbols used
HIV Ag/Ab Combo E HIV Ag/Ab Combo 2G83-20 34-9962/R8 B2G830 Read Highlighted Changes Revised March, 2008 Customer Service For additional product information, please contact your local customer service
More informationQuality Assurance Guidelines for Testing Using the OraQuick Rapid HIV-1 Antibody Test
Quality Assurance Guidelines for Testing Using the OraQuick Rapid HIV-1 Antibody Test U.S. Department of Health and Human Services Centers for Disease Control and Prevention Use of trade names and commercial
More informationTHE PREPARATION OF SINGLE DONOR CRYOPRECIPITATE
FACTS AND FIGURES JUNE 2004 NO 2 THE PREPARATION OF SINGLE DONOR CRYOPRECIPITATE Revised Edition Shân Lloyd National Blood Transfusion Service Zimbabwe Published by the World Federation of Hemophilia (WFH);
More informationRapid HIV Testing of Clients of a Mobile STD/HIV Clinic ABSTRACT
AIDS PATIENT CARE and STDs Volume 19, Number 4, 2005 Mary Ann Liebert, Inc. Rapid HIV Testing of Clients of a Mobile STD/HIV Clinic THOMAS S. LIANG, M.P.H., 1 EMILY ERBELDING, M.D., M.P.H., 3 CLAUDE A.
More informationResults of the 1999 Retroviral Testing Survey Questionnaire Sent to Laboratories Participating in the Model Performance Evaluation Program
Results of the 1999 Retroviral Testing Survey Questionnaire Sent to Laboratories Participating in the Model Performance Evaluation Program U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
More informationDistribution: General. English only
Distribution: General English only WHO Working Group on Reference Preparations for testing Diagnostic Kits used for detection of HBsAg, Anti-HCV and Anti-HIV antibodies in blood screening Report of the
More informationUsing RFID-based Inventory Management in the Clinical Lab: How We Cut Costs and Improved Productivity
Saint Francis Hospital Laboratory Using RFID-based Inventory Management in the Clinical Lab: How We Cut Costs and Improved Productivity Sharon Cox, MT(ASCP)SC Core Laboratory Supervisor Saint Francis Hospital
More informationTuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology
More informationGlobal Fund Quality Assurance for Diagnostics
Global Fund Quality Assurance for Diagnostics AIDS MEDICINES AND DIAGNOSTICS (AMDS) ANNUAL STAKEHOLDERS AND PARTNERS MEETING 29 30 September 2014 Dr Joelle DAVIAUD Quality Assurance Specialist Grant Management
More informationSYSTEM. For In Vitro Diagnostic Use. Store at 2-8 C
SYSTEM E HAVAb-IgG 6C29 B6C290 36-6800/R1 HAVAb-IgG This package insert must be read carefully prior to use. Package insert instructions must be followed accordingly. Reliability of assay results cannot
More informationU.S. Public Health Service Guidelines for Testing and Counseling Blood and Plasma Donors for Human Immunodeficiency Virus Type 1 Antigen
March 1, 1996 / Vol. 45 / No. RR-2 Recommendations and Reports U.S. Public Health Service Guidelines for Testing and Counseling Blood and Plasma Donors for Human Immunodeficiency Virus Type 1 Antigen U.S.
More informationABORhCard. ABORhCard Package Insert ABO and Rh Blood Grouping Device
ABORhCard Package Insert ABO and Rh Blood Grouping Device ABORhCard Intended Use The ABORhCard is a qualitative in vitro test that provides a simultaneous ABO and Rh determination of an individual s ABO
More informationCANADIAN RULE BASED CLASSIFICATION SYSTEM (IVDD) Life Sciences British Columbia NRC-Industry Research Assistance Program
CANADIAN RULE BASED CLASSIFICATION SYSTEM (IVDD) Life Sciences British Columbia NRC-Industry Research Assistance Program Health Canada Regulations on Medical Devices Vancouver, B.C. October 29, 2007 Nancy
More informationTOTAL PROCESS MANAGEMENT FOR YOUR NEWBORN SCREENING LABORATORY. Specimen Gate software
TOTAL PROCESS MANAGEMENT FOR YOUR NEWBORN SCREENING LABORATORY Specimen Gate software MANAGE YOUR ENTIRE SCREENING PROCESS Newborn screening generates vast amounts of data that require continuous tracking.
More informationHuCAL Custom Monoclonal Antibodies
HuCAL Custom Monoclonal Antibodies Highly Specific Monoclonal Antibodies in just 8 Weeks PROVEN, HIGHLY SPECIFIC, HIGH AFFINITY ANTIBODIES IN 8 WEEKS WITHOUT HuCAL PLATINUM IMMUNIZATION (Human Combinatorial
More informationAlgorithm for detecting Zika virus (ZIKV) 1
Algorithm for detecting Zika virus (ZIKV) 1 This algorithm is addressed to laboratories with established capacity (molecular, antigenic and/or serological) to detect dengue (DENV), Zika (ZIKV) 2, and chikungunya
More informationAll administration and correspondence is by email to: Jelena Baburina j.baburina@ucl.ac.uk. Emails will normally receive a response within 2 weeks.
UCL MEDICAL SCHOOL VISITING STUDENT ELECTIVES INFORMATION AND APPLICATION PROCESS UCL Medical School is pleased to offer a visiting student electives programme to international undergraduate medical students
More informationGuidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011
Guidelines for TB Blood Testing Minnesota Department of Health TB Prevention and Control Program June 2011 Outline Interferon-Gamma Release Assays aka TB blood tests 1. What are they? 2. What are the current
More informationXV.Quality Assurance in the Blood Bank
XV.Quality Assurance in the Blood Bank A. Overview 1. Goals 2. Terms B. Record Keeping a. Safe transfusion b. Careful adherence to SOPs by trained personnel c. Develop comprehensive guidelines to be in
More informationHIV TESTING AND D IAGNOSIS IN I NFANTS AND C HILDREN
CHAPTER 1 HIV TESTING AND D IAGNOSIS IN I NFANTS AND C HILDREN 12/04 I. INTRODUCTION Although there have been tremendous advances in the care of HIV-infected adults and children in the last several years,
More informationBorrelia burgdorferi IgG, IgM Fully automated chemiluminescence assays for quantitative determination of Borrelia antibodies in serum and CSF
Borrelia burgdorferi IgG, IgM Fully automated chemiluminescence assays for quantitative determination of Borrelia antibodies in serum and FOR OUTSIDE THE US AND CANADA ONLY Borrelia burgdorferi IgG, IgM
More informationLyme (IgG and IgM) Antibody Confirmation
Pathology & Laboratory Medicine Lyme (IgG and IgM) Antibody Confirmation TEST UPDATE: New Test Notification Date: 1/9/2013 Effective Date: 1/7/2013 CONTACT INFO Call 802-847-5121 800-991-2799 email labmarketing@vtmednet.org
More informationSTANDARD OPERATING PROCEDURE FOR THE DIRECT ANTIGLOBULIN TEST
STANDARD OPERATING PROCEDURE FOR THE DIRECT ANTIGLOBULIN TEST TITLE: Standard Operating Procedure for Performing the Direct Antiglobulin Test 1.0 Principle To detect in vivo sensitization of red blood
More informationALS and Lyme Disease Questions from Patient and Families Responses from Medical Experts
ALS and Lyme Disease Questions from Patient and Families Responses from Medical Experts Introduction: When anyone receives a diagnosis of ALS, it is normal and understandable to ask why you ve developed
More informationCustomer Resource Manual For Laboratory Testing Services
Customer Resource Manual For Laboratory Testing Services Indiana Blood Center Indianapolis, IN 46208 Version 15, January 2013 TABLE of CONTENTS Section I: General IBC Laboratory Services Information A.
More informationBlood Donor Counselling
Blood Donor Counselling Implementation Guidelines In collaboration with: Blood Donor Counselling Implementation Guidelines In collaboration with: WHO Library Cataloguing-in-Publication Data Blood donor
More informationOneStep Fecal Occult Blood RapiDip InstaTest. Cat # 13020-1
CORTEZ DIAGNOSTICS, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 USA Tel: (818) 591-3030 Fax: (818) 591-8383 E-mail: onestep@rapidtest.com Web site: www.rapidtest.com See external label
More informationSerological diagnosis of syphilis
Serological diagnosis of syphilis SI Egglestone and AJL Turner for the PHLS Syphilis Serology Working Group Summary: The availability of an increasing number of enzyme immunoassays (EIAs) for detecting
More informationResults Demographic profile of these children is shown in Table I.
Prevalence of Antibody to Hepatitis C Virus in Pakistani Thalassaemics by Particle Agglutination Test Utilizing C 200 and C 22-3 Viral Antigen Coated Particles Pages with reference to book, From 269 To
More informationThe EliA System Time for the essentials Cost efficient and flexible A boost in service for your laboratory and your clinicians
CCP The EliA System Time for the essentials completely automated (true walk-away, overnight runs) easy instrument management by Phadia Data Manager (IDM) software barcode-reader protocols, QC and raw data
More informationPROPOSED DOCUMENT. Global Harmonization Task Force. Title: Principles of In Vitro Diagnostic (IVD) Medical Devices Classification
SG1(PD)/N045R12 PROPOSED DOCUMENT Global Harmonization Task Force Title: Principles of In Vitro Diagnostic (IVD) Medical Devices Classification Authoring Group: Study Group 1 of the Global Harmonization
More informationQuality in noninfectious
Quality in noninfectious serology Willy Vandersteen o Pre-analysis o Method o Pipetting and incubation station o Reagents o Microscopy/Signal detection o People o Informatics o Post-analysis o Murphy?
More informationChapter 6: Antigen-Antibody Interactions
Chapter 6: Antigen-Antibody Interactions I. Strength of Ag-Ab interactions A. Antibody Affinity - strength of total noncovalent interactions between single Ag-binding site on an Ab and a single epitope
More informationIdentifying Celiac Disease and Gluten Sensitivity with Minimally Invasive Testing
Identifying Celiac Disease and Gluten Sensitivity with Minimally Invasive Testing Enjoy this white paper by Jack A. Maggiore, PhD, MT(ASCP), Assistant Director, Chemistry Laboratory and R&D at Doctor s
More informationHIV/AIDS: General Information & Testing in the Emergency Department
What Is HIV? HIV/AIDS: General Information & Testing in the Emergency Department HIV is the common name for the Human Immunodeficiency Virus. HIV is a retrovirus. This means it can enter the body s own
More informationCAP Accreditation Checklists 2015 Edition
CAP Accreditation Checklists 2015 Edition The College of American Pathologists (CAP) accreditation checklists contain the CAP accreditation program requirements, developed on more than 50 years of insight
More informationContent: 1) Intended use 2) Design Theory/ Brief Description of the Product 3)
Content: 1) Intended use 2) Design Theory/ Brief Description of the Product 3) Description of Materials Provided & Product Code system 4) Instruction for Use 4.1) Warnings 4.2) Specimen Collection and
More informationA s h o r t g u i d e t o s ta n d A r d i s e d t e s t s
A short guide to standardised tests Copyright 2013 GL Assessment Limited Published by GL Assessment Limited 389 Chiswick High Road, 9th Floor East, London W4 4AL www.gl-assessment.co.uk GL Assessment is
More information